Bioavailability of Vitamin B12 in Bread Using Fermented Faba Bean as B12 Source in Healthy Volunteers (BeanBread)

Sponsor
University of Helsinki (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06096298
Collaborator
(none)
25
3
2.7

Study Details

Study Description

Brief Summary

Vitamin B12 is naturally present in animal products, but it could be added to plant-based products through fermentation using the Propionibacterium freudenreichii bacterium. This study aims to investigate the absorption of vitamin B12 synthesized by Propionibacterium freudenreichii from products made with fermented faba bean. The study products are wheat breads of which 30 % of the dry weight has been replaced with fermented faba bean flour. One of the study breads contains vitamin B12 produced by P. freudenreichii bacteria, and the other bread (control bread) is fermented using L. brevis bacteria (does not produce vitamin B12). The participants will eat the study bread for two consecutive days during the study weeks, with a washout period of 12 days. Fasting blood samples are collected on day 1 before administration of the first dose of vitamin B12 and on day 3. Nutrient intake and food consumption will be analyzed from 3-day food records at the baseline and on the bread eating days. The study is carried out in a double-blinded crossover setting.

Condition or Disease Intervention/Treatment Phase
  • Other: Vitamin B12 bread
  • Other: Control bread
N/A

Detailed Description

A human intervention study with healthy volunteers will be carried out to investigate the absorption of vitamin B12 synthesized by Propionibacterium freudenreichii from bread made with fermented faba bean. The study is conducted on healthy, 18-50-year-old volunteers. The study is carried out in a randomized, double-blinded, placebo-controlled crossover design.

The study products are wheat breads of which 30% of the dry weight has been replaced with fermented faba bean flour. One of the study breads contains fermented faba bean flour containing vitamin B12 produced by P. freudenreichii bacteria, and the other bread (control bread) contains faba bean flour fermented with L. brevis bacteria (does not produce vitamin B12). In addition to the study breads, the study participants are given a vitamin supplement containing cyanocobalamin as a positive control during one study week and a placebo supplement as a negative control for two weeks. During each study period, the subjects eat study breads and supplements for two consecutive days, three times a day. The study participants are otherwise allowed to follow their usual diet. On the morning of the first and third study day of each study period, a blood sample is taken from the subjects, from which the vitamin B12 bound to holotranscobalamin II and the total vitamin B12 concentration in the serum are determined. At the baseline of the study, the blood samples are also analyzed for folate, methylmalonate, homocysteine and creatinine concentrations.

Nutrient intake and food consumption will be analyzed from 3-day food records during the run-in week and each study week (total 9 days). The participants will report their gastrointestinal symptoms during the study periods.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Masking Description:
The study is double-masked - neither the researchers or the participants know which bread they are eating.
Primary Purpose:
Prevention
Official Title:
Bioavailability of Vitamin B12 in Bread Using Fermented Faba Bean as B12 Source in Healthy Volunteers (BeanBread)
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Dec 22, 2023
Anticipated Study Completion Date :
Dec 22, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Vitamin B12 bread

Daily dose of bread containing B12 (15 µg of vitamin B12/d) and placebo tablet (0 µg of vitamin B12/d) for 2 consecutive days.

Other: Vitamin B12 bread
Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour containing vitamin B12 produced by P. freudenreichii bacteria.

Active Comparator: Positive control

Daily dose of control bread (0 µg of vitamin B12/d and B12 tablet (15 µg of vitamin B12/d) for 2 consecutive days.

Other: Control bread
Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour.

Placebo Comparator: Negative control

Daily dose of control bread (0 µg of vitamin B12/d and placebo tablet (0 µg of vitamin B12/d) for 2 consecutive days.

Other: Control bread
Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour.

Outcome Measures

Primary Outcome Measures

  1. Vitamin B12 bound to transcobalamin II (holoTc) [2 days]

    Changes in serum holotranscobalamin concentrations after intake of vitamin B12

  2. Total B12 [2 days]

    Changes in serum total B12 concentrations after intake of vitamin B12

Secondary Outcome Measures

  1. The intensity of gastrointestinal symptoms measured by a visual analogue scale [4 weeks]

    Study participants report the intensity of experienced stomach pain, cramps, bloating, flatulence, stomach noise, nausea, heartburn, unpleasant feeling and sudden need to defecate on a scale of zero (no pain at all) to 100 (very intense pain)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy

  • Body mass index between 18.5 and 35 kg/m2

  • No exclusion criteria listed below

Exclusion Criteria:
  • Food allergies against ingredients in foods supplemented in the study

  • pregnancy and/or breastfeeding

  • Regular use of food supplements containg B12

  • Blood donation within 3 months

  • Alcohol consumption more than 24 measures per week

  • Smoking, using snuff

  • Iron, B12 or folate deficiency

  • Anemia

  • small intestinal bacterial overgrowth (SIBO)

  • Gastritis

  • Helicobacter pylori infection

  • Acid reflux

  • Chron's disease

  • Celiac disease

  • Pancreatitis

  • Abdominal surgery

  • Eating disorder

  • Use of supplements containing vitamin B12 in the last year

  • Vitamin B12 injection treatment in the last year

  • Use of metformin, protein pump inhibitors or H2-receptor blockers

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Helsinki

Investigators

  • Principal Investigator: Anne-Maria Pajari, PhD, University of Helsinki

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Anne-Maria Pajari, Associate Professor, University of Helsinki
ClinicalTrials.gov Identifier:
NCT06096298
Other Study ID Numbers:
  • BeanBread-HY
First Posted:
Oct 23, 2023
Last Update Posted:
Oct 25, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Anne-Maria Pajari, Associate Professor, University of Helsinki
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 25, 2023